novo obesity - Search News

Novo Nordisk Shares Fall

Novo’s New Obesity Drug Disappoints Again, This Time in Diabetes

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some investors’ expectations in a clinical trial of people with diabetes.

The Wall Street Journal on MSN · 3d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Reuters on MSN · 3d

Novo Nordisk's new obesity drug data disappoints again, shares fall

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market. Lisa Bernhard has more.

Novo Nordisk Skeptic Finally Upgrades Stock

Bloomberg L.P. · 1d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Markets Insider · 22h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Seeking Alpha · 1d

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

Novo Nordisk foundation’s obesity head works as paid adviser to chocolate maker Ferrero

Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

MedCity News4d

Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss

A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...

STAT2d

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

19h

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

3don MSN

Roche Hires Novo Executive to Help Push Into Obesity Drug Market

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results